News

Enzene to Launch Drug Discovery Division at BIO 2024

May 30, 2024

The company’s new division will provide end-to-end integrated discovery services.

Sanofi Gets Priority Review Status for sBLA Seeking Approval of Sarclisa in Combination Therapy for Multiple Myeloma

May 30, 2024

FDA granted priority review to Sanofi's sBLA for Sarclisa in combination with VRd in treating transplant-ineligible patients who are newly diagnosed with multiple myeloma.

FDA Approves Interchangeable Biosimilar to Soliris

May 30, 2024

Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Johnson & Johnson to Acquire Global Rights to Numab Therapeutics’ Bispecific Antibody for Atopic Dermatitis in $1.25 Billion Deal

May 30, 2024

Johnson & Johnson will gain NM26, a bispecific antibody targeting atopic dermatitis, via the acquisition of a wholly owned subsidiary of Numab Therapeutics.

Integrated Biosciences Collaborates with Illumina Ventures Labs Collaborate on Novel Therapeutics

May 29, 2024

The partnership will create therapeutic assets and new discovery platforms and potentially reshape drug discovery.

Highlighting Personalized mRNA-Based Vaccines for Pancreatic Cancer (ASGCT 2024)

May 25, 2024

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

AGC Biologics Partners with BioConnection to Offer Biopharma Drug Substance and Drug Product Development and Manufacturing

May 25, 2024

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

Biogen to Acquire HI-Bio in Deal Worth Potentially Up to $1.8 Billion

May 24, 2024

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

May 24, 2024

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

Hospira Recalls Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection, USP Carpuject Units

May 23, 2024

The units are being recalled because of incomplete crimp seals and one complaint of a leaking unit.